Premaitha Health PLC Premaitha to Attend International Medical Events

TIDMNIPT

Premaitha Health PLC

13 March 2017

Premaitha Health PLC

("Premaitha" or the "Company")

Premaitha Raises Awareness of the IONA(R) Test

at Key International Medical Events

Manchester, UK - 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, will be attending a series of key international fetal medicine and OB/GYN events during March to broaden awareness of the IONA(R) test. The events will include:

The Royal College of Obstetricians and Gynaecologists (RCOG) World Congress 2017

The RCOG World Congress 2017 will be held in Cape Town, South Africa between 20 - 22 March 2017. Premaitha will host an exhibition booth showcasing the IONA(R) test to a large number of obstetrician and gynaecologist professionals from around the world. For further details, visit: www.rcog2017.com.

Forum Labo

Forum Labo will be held in Paris, France between 28 - 30 March 2017. Executives from Premaitha will attend this event together with the Company's French distributor, Adgenix, to promote the benefits of the IONA(R) test to the large number of laboratory professionals from France that will be in attendance. For further details, visit: www.forumlabo.com.

The British Maternal and Fetal Medicine Society (BMFMS), 19(th) Annual Conference

The BMFMS 19th Annual Conference will be held in Amsterdam, The Netherlands between 30 - 31 March 2017. As a Gold Sponsor, Premaitha will have a significant presence at the event, hosting an exhibition booth and an educational symposium on non-invasive prenatal screening. The delegates will hear from three key opinion leaders - who are also Premaitha customers - discussing different topics relating to the IONA(R) test. The speakers will include leading obstetricians:

   --     Dr Asma Khalil from St George's NHS Hospital; 
   --     Dr Francois Jacquemard from the American Hospital in Paris; and 
   --     Dr Kelly Cohen from Leeds NHS Teaching Hospital Trust. 

In addition, there will be two clinical posters presented by two further IONA(R) test clinicians from the UK. For further details, visit: www.bmfmsconference.ukevents.org.

The 7(th) Congress of the Asia Pacific Initiative on Reproduction (ASPIRE)

ASPIRE 2017 will be held in Kuala Lumpur, Malaysia between 30 March - 2 April 2017. Premaitha will host an exhibition booth in partnership with the Company's Malaysian distributor, Analisa Scientific, showcasing the IONA(R) test to the region's clinicians, nurses, researchers and academics operating in the field of reproductive medicine and fertility. For further details, visit: www.aspire2017.com.

Dr Stephen Little, CEO of Premaitha Health, commented: "Raising awareness of the superiority of the IONA(R) test among the international OB/GYN community is key to helping drive samples to our customers' laboratories. March is expected to be a very busy month in the ongoing educational programme."

For more information, please contact:

 
 Premaitha Health PLC                  Tel: +44 (0) 
                                        161 667 6865 
 Dr Stephen Little, Chief Executive 
  Officer 
 Barry Hextall, Chief Financial 
  Officer 
 [e-mail] 
 
 Vigo Communications                   Tel: +44 (0) 
                                        20 7830 9700 
 Ben Simons / Fiona Henson / Antonia 
  Pollock 
 [e-mail] 
 

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha's IONA(R) test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA(R) test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA(R) test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA(R) test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGUPAWUPMGQU

(END) Dow Jones Newswires

March 13, 2017 03:01 ET (07:01 GMT)